Download PDF
Onkologische Welt 2017; 08(06): 278-281
DOI: 10.1055/s-0038-1639655
DGHO 2017 Stuttgart
Schattauer GmbH

Fortschritte bei der Therapie – ein Update

Akute lymphatische Leukämie
Helmine Braitmaier Dr.
Further Information

Publication History

Publication Date:
10 March 2018 (online)

    Permissions and Reprints

Die akute lymphatische Leukämie (ALL) ist die häufigste bösartige Erkrankung im Kindesalter. Auf dem DGHO-Kongress beschäftigte sich ein Symposium mit den aktuellen Therapiekonzepten – von der Chemotherapie bis zur CART-Zelle.

 

  • Literatur

  • 1 Möricke A. et al. Dexamethason vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016; 127 (17) 2101-2112.
    CrossrefGoogle Scholar
  • 2 Dagdan E. et al. The strong prognostic effect of concurrent deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG deletions (IKZF1plus) in pediatric Acute Lymphoblastic Leukemia strongly depends on minimal residual disease burden after induction treatment. Blood 2014; 124: 131.
    Google Scholar
  • 3 Iacobucci I, Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia. JCO 2017; 35 (09) 975-983.
    CrossrefGoogle Scholar
  • 4 Roberts KG. et al. Targetable kinase-activating lesions in Ph-like Acute Lymphoblastic Leukemia. NEJM 2014; 371: 1005-1015.
    CrossrefGoogle Scholar
  • 5 Santiago R. et al. Novel therapy for childhood acute lymphoblastic leukemia. Expert Opin Pharmacother 2017; 18 (11) 1081-1099.
    CrossrefGoogle Scholar
  • 6 Hagemeijer A, Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010; 49 (04) 299-308.
    Google Scholar
  • 7 Katarjian HM. et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. NEJM 2017; 376 (09) 836-847.
    CrossrefGoogle Scholar
  • 8 Katarjian HM. et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. NEJM 2016; 375 (08) 740-753.
    CrossrefGoogle Scholar
  • 9 Gökbuget N. et al. BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood. 2014
    Google Scholar
  • 10 Buechner J. et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) ALL: Update to the Interim Analysis. EHA 2017, Abstract S476.
    Google Scholar
  • 11 Hay KA. et al. Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy. Blood. 2017 Vorabpublikation, doi: 10.1182/blood-2017–06–793141.
    Google Scholar